Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Shares Shorted: Short Interest Down 63.0% in October

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB – Get Free Report) saw a significant decrease in short interest in the month of October. As of October 30th, there was short interest totaling 5,139 shares, a decrease of 63.0% from the October 15th total of 13,889 shares. Based on an average daily trading volume, of 48,290 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the company’s shares are short sold.

Analyst Ratings Changes

CMMB has been the topic of a number of research reports. Wall Street Zen upgraded shares of Chemomab Therapeutics to a “hold” rating in a research report on Saturday, October 3rd. Weiss Ratings upgraded Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Chemomab Therapeutics presently has a consensus rating of “Reduce”.

Check Out Our Latest Analysis on Chemomab Therapeutics

Chemomab Therapeutics Stock Up 8.6%

NASDAQ:CMMB traded up $0.13 during trading hours on Monday, hitting $1.66. 64,818 shares of the company traded hands, compared to its average volume of 93,993. Chemomab Therapeutics has a one year low of $0.92 and a one year high of $2.99. The company has a market cap of $12.04 million, a PE ratio of -0.78 and a beta of 0.80. The firm’s 50-day simple moving average is $1.65 and its 200-day simple moving average is $1.74.

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last posted its earnings results on Thursday, August 20th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.12).

Chemomab Therapeutics Company Profile

(Get Free Report)

Chemomab Therapeutics is an Israel-based clinical-stage biopharmaceutical company developing treatments for inflammatory and fibrotic diseases. Its research focuses on CCL24, a signaling protein the company believes contributes to inflammation and tissue scarring. The company’s lead candidate, CM-101, is a monoclonal antibody designed to block CCL24. Chemomab has studied the candidate in conditions including primary sclerosing cholangitis and systemic sclerosis. Chemomab was previously a privately held company and became publicly traded in 2021 through a merger with Anchiano Therapeutics.

See Also

Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.